15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      High and variable population prevalence of HLA‐B*56:02 in indigenous Australians and relation to phenytoin‐associated drug reaction with eosinophilia and systemic symptoms

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Phenytoin drug reaction with eosinophilia and systemic symptoms (DRESS) in 3 Aboriginal Australians positive for HLA‐B*56:02 has been previously reported. We report the allele frequency of HLA‐B*56:02 in 2 South Australian populations, 1 Aboriginal (4.8%, 95% confidence interval 2.4–7.8%) and the other European (0%). We compared the frequency with publicly available information on HLA‐B*56:02 status in other Indigenous Australian ( n = 4) and European Australian cohorts ( n = 1). In the Indigenous Australian cohorts , HLA‐B*56:02 allele frequency ranged from 1.3 to 19%. We also describe an additional case of phenytoin DRESS (RegiSCAR DRESS score 7) in an Aboriginal Australian that was associated with HLA‐B*56:02 and with CYP2C9*1/*3 genotype. In Aboriginal Australians, phenytoin DRESS appears distinctly linked to HLA‐B*56:02 with an allele carriage rate substantially higher than in Europeans, but also with considerable regional variation. Investigations of human leucocyte antigen and other contributing genes and severe adverse drug reactions in understudied non‐European populations are required to optimize safe medication use and inform risk mitigation strategies.

          Related collections

          Author and article information

          Contributors
          andrew.somogyi@adelaide.edu.au
          Journal
          Br J Clin Pharmacol
          Br J Clin Pharmacol
          10.1111/(ISSN)1365-2125
          BCP
          British Journal of Clinical Pharmacology
          John Wiley and Sons Inc. (Hoboken )
          0306-5251
          1365-2125
          19 July 2019
          September 2019
          : 85
          : 9 ( doiID: 10.1111/bcp.v85.9 )
          : 2163-2169
          Affiliations
          [ 1 ] Discipline of Pharmacology, Adelaide Medical School University of Adelaide Adelaide Australia
          [ 2 ] Department of Clinical Pharmacology Royal Adelaide Hospital Adelaide Australia
          [ 3 ] Department of Medicine, Pharmacology, Oates Institute for Experimental Therapeutics, Department of Pathology, Microbiology and Immunology Vanderbilt University Nashville Tennessee USA
          [ 4 ] Institute for Immunology and Infectious Diseases Murdoch University Murdoch Australia
          [ 5 ] Department of Pharmacy Royal Adelaide Hospital Adelaide Australia
          [ 6 ] General Medicine Royal Adelaide Hospital Adelaide Australia
          [ 7 ] Department of Medicine University of Adelaide Adelaide Australia
          Author notes
          [*] [* ] Correspondence

          Professor Andrew Somogyi, Discipline of Pharmacology, Adelaide Medical School, University of Adelaide, Adelaide 5005, Australia.

          Email: andrew.somogyi@ 123456adelaide.edu.au

          Author information
          https://orcid.org/0000-0003-4779-0380
          https://orcid.org/0000-0001-6261-353X
          https://orcid.org/0000-0002-1888-4188
          https://orcid.org/0000-0002-2969-7900
          Article
          PMC6710506 PMC6710506 6710506 BCP14025 MP-00239-19.R1
          10.1111/bcp.14025
          6710506
          31206740
          6146e1ee-3e2b-4da2-ac7b-82d37831350b
          © 2019 The British Pharmacological Society
          History
          : 16 March 2019
          : 19 May 2019
          : 02 June 2019
          Page count
          Figures: 2, Tables: 1, Pages: 7, Words: 2565
          Funding
          Funded by: National Health and Medical Research Council
          Award ID: NHMRC Project Grant APP108798
          Categories
          Short Report
          Short Reports
          Custom metadata
          2.0
          bcp14025
          September 2019
          Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.7 mode:remove_FC converted:27.08.2019

          human leucocyte antigen,drug toxicity,indigenous Australians,drug reaction with eosinophilia and systemic symptoms,phenytoin

          Comments

          Comment on this article